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Abstract
Aneurysmal bone cyst (ABC) is an aggressive, pediatric bone tumor characterized by extensive
destruction of the surrounding bone. Though first described over 60 years ago, its molecular
etiology remains poorly understood. Recent work revealed that ABCs harbor translocation of
TRE17/USP6, leading to its transcriptional upregulation. TRE17 encodes a ubiquitin-specific
protease (USP), and a TBC domain that mediates binding to the Arf6 GTPase. However, the
mechanisms by which TRE17 overexpression contributes to tumor pathogenesis, and the role of
its USP and TBC domains are unknown. ABCs are characterized by osteolysis, inflammatory
recruitment, and extensive vascularization, processes in which matrix proteases play a prominent
role. This led us to explore whether TRE17 regulates the production of matrix metalloproteinases
(MMPs). In the current study, we demonstrate that TRE17 is sufficient to induce expression of
MMP-9 and MMP-10, in a manner requiring its USP activity, but not its ability to bind Arf6.
TRE17 induces transcription of MMP-9 through activation of NFκB, mediated in part by the
GTPase RhoA and its effector kinase, ROCK. Furthermore, xenograft studies demonstrate that
TRE17 induces formation of tumors that reproduce multiple features of ABC, including a high
degree of vascularization, with an essential role for the USP domain. In sum, these studies reveal
that TRE17 is sufficient to initiate tumorigenesis, identify MMPs as novel TRE17 effectors that
likely contribute to ABC pathogenesis, and define the underlying signaling mechanism of their
induction.
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INTRODUCTION
Ubiquitin-specific proteases (USPs) constitute a large subfamily of de-ubiquitinating
enzymes that function in diverse cellular processes, including the DNA damage response,
inflammation, and oncogenesis (Amerik and Hochstrasser, 2004; Singhal et al., 2008;
Komander et al., 2009). Several USPs have been implicated in human tumorigenesis.
HAUSP/USP7 is a key regulator of the p53 tumor suppressor (Li et al., 2002). HAUSP de-
ubiquitinates p53 to rescue it from proteasomal degradation. CYLD encodes a tumor
suppressor that is mutated in familial cylindromatosis, an autosomal dominant disease
characterized by benign tumors arising from cells of skin appendages. CYLD is a negative
regulator of the transcription factor nuclear factor-κB (NFκB), and functions by de-
ubiquitinating the ubiquitin ligases TRAF-2 and TRAF-6 (Brummelkamp et al., 2003;
Kovalenko et al., 2003; Trompouki et al., 2003).
Another USP strongly implicated in human neoplasia is TRE17/USP6, which is translocated
at high frequency in aneurysmal bone cyst (ABC), a pediatric osseous neoplasm (Cottalorda
and Bourelle, 2007; Saccomanni, 2008). Though benign, ABCs cause extensive bone
degradation and impinge on surrounding tissue due to their expansile nature, causing pain,
swelling, deformity, neurological symptoms, and pathologic fracture (Cottalorda and
Bourelle, 2007; Saccomanni, 2008). Though first described over 60 years ago, the etiology
of ABC has remained poorly understood. They were long thought to be reactive lesions,
arising from local vascular disturbances. However, recent work showed that translocation of
TRE17 occurs in over 60% of ABC cases, revealing their neoplastic origin
(Panoutsakopoulous et al., 1999; Althof et al., 2004; Oliveira et al., 2004a; Oliveira et al.,
2004b; Oliveira et al., 2005; Sukov et al., 2008). Five different fusion partners of TRE17
have been identified, and in every case translocation resulted in promoter swapping, where
the complete coding sequence of TRE17 was placed downstream of the highly active
promoter of its fusion partner, leading to its transcriptional upregulation (Oliveira et al.,
2004a; Oliveira et al., 2004b; Oliveira et al., 2005). Notably, TRE17 is absent or expressed
at very low levels in most adult human tissues except for testes (Paulding et al., 2003).
These studies strongly suggest that TRE17 overexpression plays a key role in the etiology of
ABC. Histologically, ABCs are complex lesions consisting of blood-filled cysts, separated
by fibrous stromal areas containing spindle cells, inflammatory cells, and numerous
capillaries. Strikingly, TRE17 translocation occurs exclusively in spindle cells within the
fibrous stroma that are believed to represent an early phase of osteoblast differentiation
(Oliveira et al., 2004b). This is supported by the fact that the promoters of TRE17’s fusion
partners are highly active during osteoblast differentiation and bone formation (Oliveira et
al., 2004a; Oliveira et al., 2004b; Oliveira et al., 2005). Indeed, one fusion partner, OMD, is
expressed selectively in osteoblasts. Furthermore, osteoid (the organic component of bone
matrix produced by osteoblasts) is commonly present in these lesions. Together, these
observations suggest that cells overexpressing TRE17 in ABCs are immature cells of the
osteoblast lineage. However, the mechanism by which overexpression of TRE17 in
osteoblasts contributes to the formation of these complex, cellularly heterogeneous lesions is
completely unknown.
Two naturally occurring splice variants of TRE17 exist (Nakamura et al., 1992; Paulding et
al., 2003), giving rise to isoforms termed TRE17(long) and TRE17(short) (previously
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termed TRE17(onco)). They are identical through the first 773 amino acids, but then
diverge: TRE17(long) encodes a USP, which comprises cysteine and histidine subdomains,
both of which are required for catalytic activity (Papa and Hochstrasser, 1993).
TRE17(short) is truncated shortly after the cysteine subdomain. Both isoforms contain an N-
terminal TBC (TRE2-Bub2-Cdc16) domain. TBC domains are generally predicted to encode
GTPase-activating proteins (GAPs) for Rab family GTPases (Bernards, 2003). However, we
and others have shown that the TBC domain of TRE17 lacks catalytic activity, and that it
functions instead to mediate interaction with the small GTPase, Arf6 (Martinu et al., 2004;
Bizimungu and Vandenbol, 2005; Bizimungu et al., 2007). We further reported that TRE17
promotes activation of Arf6 in vivo (Martinu et al., 2004). However, the mechanism by
which TRE17 contributes to ABC pathogenesis, and the roles of its TBC and USP domains,
remain largely unknown. Here, we identify matrix metalloproteinases as novel effectors of
TRE17, and dissect the signaling pathways leading to their induction. We further
demonstrate that TRE17 is sufficient to induce the formation of tumors that recapitulate
muliple features of ABC, in a manner that requires its USP domain.
RESULTS
TRE17 induces production of MMP-9 and MMP-10 in a USP-dependent manner
ABCs are characterized by extensive bone degradation, inflammatory recruitment, and
angiogenesis, processes in which matrix proteases play a key role. Furthermore, a previous
immunohistochemical study showed that the fibrous stromal regions of ABC stain strongly
for matrix metalloproteinase-9 (MMP-9) (Kumta et al., 2003). This led us to explore
whether TRE17 contributes to ABC pathogenesis by regulating production of MMPs. Using
an unbiased antibody-based array to screen the conditioned medium (CM) of transfected
cells, we found that TRE17 induced the accumulation of MMP-9 and MMP-10
(Supplemental Figure 1). These array results were confirmed by direct immunoblotting,
performing studies in osteoblastic cells, the lineage that harbors translocation/
overexpression of TRE17 in ABC. As shown in Figure 1A, transient expression of
TRE17(long) in hFOB1.19, a human pre-osteoblastic cell line (Subramaniam et al., 2002),
induced production of MMP-9 and MMP-10, as determined by immunoblotting of CM from
serum-starved cells.
We next examined the roles of TRE17’s TBC and USP domains in MMP induction. To
determine the requirement for TRE17’s USP activity, we tested the naturally occurring
TRE17(short) isoform, as well as a catalytically inactive point mutant (TRE17(long)/USP-)
(Shen et al., 2005) (Figure 1B). As seen in Figure 1A, both of these alleles failed to induce
MMP production in hFOB1.19 cells. We also assessed the role of the TBC domain, which
we previously reported mediates binding to Arf6 (Martinu et al., 2004). We generated a
triple point mutant within the TBC domain that ablates binding to Arf6 (denoted
TRE17(A6-)) (Figure 1B and 1C). This mutant was competent to induce MMP production
as well as TRE17(long) (Figure 1A). Together, these data indicate that TRE17’s USP
activity, but not its ability to bind Arf6, is required for the induction of MMP- and MMP-10.
We wished to confirm these results in an independent osteoblastic system, under conditions
of stable expression. For this purpose, MC3T3-E1 murine pre-osteoblasts (Wang et al.,
1999), referred to hereafter as MC3T3, were engineered to stably express TRE17 alleles in a
doxycyclin (dox)-inducible manner. Figure 1D demonstrates uniform expression of the
various mutants, strictly in the presence of dox. MC3T3 cell lines expressing TRE17(short)
were also generated, however its expression levels were significantly reduced relative to the
other alleles (data not shown). Therefore, cells expressing TRE17(long)/USP- were used in
subsequent experiments to examine the role of the USP domain. Dox-dependent induction of
MMP-9 was observed in the MC3T3 lines expressing TRE17(long) and TRE17(A6-), as
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determined by both immunoblotting and zymography, which measures gelatinolytic activity
(Figure 1D). In contrast, TRE17(long)/USP- was significantly impaired in stimulating
MMP-9 production (Figure 1D). Effects on MMP-10 could not be confirmed in these cells
by immunoblotting, since antibodies that recognize the murine protein are not available.
However, alternative detection methods revealed that it was also induced (see next section).
We next explored whether MMP induction by TRE17 was specific to osteoblasts, or could
be elicited in other cell types. To test this, TRE17 alleles were transfected into HeLa cells, a
cervical carcinoma. As seen in Figure 1E, TRE17(long) was capable of inducing robust
expression of MMP-9 and MMP-10 in these cells, again in a USP-dependent manner. Thus,
TRE17’s ability to stimulate matrix protease production is not restricted to osteoblasts. As
mentioned above, previous work showed that ABC tumors stain strongly for MMP-9
(Kumta et al., 2003), but the cells responsible for its production had not been identified. Our
data demonstrate that TRE17 is sufficient, in the absence of any serum-derived factors, to
induce production of MMPs, and suggest that it may be directly responsible for their
production in ABCs.
TRE17 stimulates MMP expression on a transcriptional level
We next sought to determine the mechanism by which TRE17 induces production of MMPs.
Because transcriptional induction is the most common mode of MMP regulation, (Sternlicht
and Werb, 2001; Mott and Werb, 2004), we examined whether TRE17 increased the
abundance of MMP mRNA. RNA was isolated from transfected hFOB1.19 or HeLa, or the
MC3T3 stable lines. RT-quantitative PCR was performed using two independent primer
pairs for each MMP, and normalized against GAPDH. In all three systems, levels of MMP-9
and MMP-10 mRNA were elevated in cells expressing TRE17(long), but not TRE17(short)
or TRE17(long)/USP- (Figure 2A-C).
We next tested whether increased MMP expression resulted from transcriptional induction.
We focused on MMP-9 since its expression in ABC had been previously demonstrated, and
there exists a wealth of information on its regulation as well as reagents for its analysis.
Reporter assays were performed using a luciferase construct driven by base pairs −674 to +3
of the human MMP-9 promoter (Liu et al., 2006). In both hFOB1.19 and Hela, TRE17(long)
activated the MMP-9 promoter approximately 5-fold over control vector transfected samples
(Figure 2D). TRE17(short) and TRE17(long)/USP− were significantly compromised in
activation of the reporter. Transient reporter assays could not be performed in the MC3T3
cell lines as they were engineered to stably and inducibly express luciferase. Nevertheless,
these data in sum reveal that TRE17 induces transcription of MMP-9 in a USP-dependent
manner.
NFκB is required for induction of MMP-9 by TRE17
Two key regulators of the MMP-9 promoter are NFκB (Liu et al., 2006) and AP-1 (Cho et
al., 2000; Genersch et al., 2000; Kim and Lee, 2005; Han et al., 2006). To ascertain their
roles in MMP-9 induction, we first analyzed a reporter construct mutated in the NFκB
response element (Liu et al., 2006). Loss of the NFκB-binding site abrogated activation of
the MMP-9 promoter by TRE17(long) in hFOB1.19 and HeLa (Figure 3A), indicating that
NFκB is the key mediator of TRE17-induced MMP-9 gene transcription.
To confirm the dominant role of NFκB in induction of endogenous MMP-9 by TRE17, we
examined the effects of inhibitors of the NFκB and AP-1 pathways on MMP-9 secretion.
NFκB activation was blocked using Bay11-7082 (Pierce et al., 1997). Bay11-7082 caused a
dose-dependent reduction in levels of MMP-9 induced by TRE17(long), in hFOB1.19 and
MC3T3 cells (Figure 3B). However, U0126, which inhibits AP-1 activation by preventing
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its phosphorylation by Erk, had no effect on MMP-9 secretion (Figure 3B). To confirm the
requirement for NFκB, we tested the effects of three additional structurally unrelated NFκB
pathway inhibitors, wedelolactone, SC-514, and IKK Inhibitor XI. As shown in Figure 3C,
all three drugs significantly inhibited MMP-9 production in both HeLa and MC3T3 cells.
Together, these results confirm that induction of MMP-9 by TRE17(long) is predominantly
mediated through NFκB.
TRE17 activates NFκB in a USP-dependent manner
The requirement for NFκB in MMP-9 production led us to explore whether TRE17 activates
NFκB. As shown in Figure 4A, TRE17(long) potently activated an NFκB-responsive
luciferase reporter in both hFOB1.19 and HeLa, while TRE17(short) and TRE17(long)/
USP− were attenuated by comparison. Activation of NFκB by TRE17(long) was confirmed
by electrophoretic mobility shift assays (EMSA) (Figure 4B), and by monitoring its
subcellular localization (Figure 4C). NFκB, which comprises p65 and p50 subunits, is
maintained in an inactive state through its cytoplasmic retention by IκB; activation is
reflected by nuclear translocation of p65/p50. In control hFOB1.19, p65 exhibited diffuse
cytoplasmic staining and was largely excluded from the nucleus (Figure 4C). In contrast, in
cells expressing TRE17(long), but not TRE17(short) or TRE17(long)/USP-, p65
accumulated in the nucleus (Figure 4C). Similar results were seen in Hela cells and in the
MC3T3 cell lines (data not shown). Together, these data confirm that TRE17 activates
NFκB in a USP-dependent manner.
RhoA/ROCK mediate NFκB activation and MMP-9 production by TRE17
We next explored the signaling mechanism by which TRE17 induces activation of NFκB.
NFκB can be activated by a wide variety of signaling molecules, including Rho family
GTPases. During the course of our studies, we noted that cells expressing TRE17 exhibited
alterations in morphology that were consistent with activation of RhoA (Nobes and Hall,
1995a; Nobes and Hall, 1995b). Specifically, they had a greatly increased number of focal
adhesions distributed throughout the cell (data not shown). To determine whether RhoA was
activated by TRE17, we performed pulldown assays using the Rho-binding domain (RBD)
of Rhotekin (which binds to RhoA in a GTP-dependent manner) as an affinity reagent.
Expression of TRE17(long) in hFOB1.19 or HeLa induced robust activation of RhoA
(Figure 5A). Activation of RhoA was also observed in TRE17(long)/MC3T3, in a dox- and
USP-dependent manner (Figure 5A).
Previous work had demonstrated that RhoA potently activates NFκB, functioning through
its effector kinase, ROCK (Benitah et al., 2003; Anwar et al., 2004; Nakakuki et al., 2005;
Cui et al., 2006). This led us to investigate whether RhoA and ROCK mediate TRE17-
induced activation of NFκB. Co-expression of dominant negative RhoA partially attenuated
activation of the NFκB-luc reporter by TRE17(long), in both hFOB1.19 and HeLa cells
(Figure 5B). Furthermore, treatment of cells with the ROCK inhibitor Y27632 also partially
inhibited NFκB activation by TRE17(long), in a dose-dependent manner (Figure 5B).
Since we showed that NFκB is essential for induction of MMP-9, we predicted that Y27632
should also block MMP-9 production. Accordingly, we found that Y27632 caused a dose-
dependent reduction in MMP-9 levels induced by TRE17(long)/MC3T3, as determined by
immunoblotting and zymography (Figure 5C). Collectively, our data define a pathway in
which TRE17, in a USP-dependent manner, activates RhoA/ROCK, leading to NFκB
activation and resultant production of MMP-9.
Ye et al. Page 5
Oncogene. Author manuscript; available in PMC 2010 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
TRE17 induces formation of tumors that recapitulate multiple features of ABC in a USP-
dependent manner
In sum, our in vitro analysis demonstrates that TRE17 is sufficient to induce expression of
MMPs, which we propose contributes to ABC pathogenesis. MMPs (MMP-9 in particular)
play a central role in angiogenesis and inflammation, processes which typify ABC lesions.
This led us to examine whether xenografts of TRE17(long)-expressing MC3T3 recapitulate
molecular features of this tumor. We elected to introduce cells into mice subcutaneously
rather than intra-osseously in order to facilitate both delivery and monitoring of the
xenograft. Subcutaneous placement of the xenograft is physiologically relevant since ABCs
can arise in soft tissues, and are histologically identical to osseous cases (Nielsen et al.,
2002; Sukov et al., 2008).
MC3T3-derived lines were injected subcutaneously into flanks of nude mice, and expression
of TRE17(long) and luciferase was induced in vivo by addition of dox to the drinking water.
Palpable growths were visible as early as 5-7 days post-injection in all 9 mice injected with
TRE17(long)/MC3T3, exclusively in the presence of dox. Tumors reached maximal size
(from 3-10 mm in diameter) within 2 weeks. No palpable tumors were observed in any mice
injected with MC3T3 expressing TRE17(long)/USP-, TRE17(short), or luciferase alone.
To assess tumorigenesis quantitatively, in vivo bioluminescence imaging was performed.
Animals were injected intraperitoneally with luciferin, then imaged using the Xenogen In
Vivo Imaging System to detect the luciferase-expressing xenografted cells. While all
animals injected with TRE17(long)/MC3T3 cells emitted a strong bioluminescence signal,
mice injected with cells expressing TRE17(long)/USP-, TRE17(short), or luciferase alone
gave signals approximately 10-fold weaker (Figure 6A and data not shown). These results
reveal that TRE17’s USP activity is essential for tumorigenesis.
Dissection of animals injected with TRE17(long)/MC3T3 cells revealed the presence of
solid tumors with a striking hemorrhagic appearance (Figure 6B). Hematoxylin and eosin
staining revealed that this arose from extensive vascularization as well as blood
extravasation (Figure 6B), both of which are prominent features of ABC. Lesions were
composed of a spindle cell population associated with a fibrous or myxoid matrix (Fig 6B),
also highly reminiscent of ABC (Oliveira et al., 2004b; Shinde et al., 2006). No tumors or
vascularization were seen upon dissection of mice injected with control or TRE17(long)/
USP−-expressing MC3T3 cells (Figure 6B). Immunohistochemical analysis of serial tumor
sections revealed strong MMP-9 staining of the TRE17-positive cells (Figure 6C). These
results not only provide in vivo confirmation of our in vitro results, but also recapitulate the
MMP-9 enrichment observed in the stroma of ABC tumors (Kumta et al., 2003). Thus, our
data demonstrate that this osteoblastic model reproduces multiple features of ABC, and
strongly validate its use for dissecting the molecular functions of TRE17 in ABC
pathogenesis.
DISCUSSION
Although aneurysmal bone cyst was first described over 60 years ago, remarkably little
progress has been made in elucidating its pathogenesis. The discovery in 2004 that
translocation of TRE17/USP6 occurs in the majority of ABC cases represented a significant
advance. However, many key questions have remained unanswered regarding TRE17’s role
in the etiology of this tumor, including whether TRE17 overexpression is sufficient to
initiate tumor formation, the molecular pathways it engages, and the role of its USP domain.
Our study provides insights into all of these key issues. We show that overexpression of
TRE17 in pre-osteoblastic MC3T3 cells is sufficient to drive the formation of tumors that
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reproduce molecular and histological features of ABC. Interestingly, TRE17(long) tumors
remained as solid masses, and did not form the multicystic lesions typically seen in ABC.
Thus, although TRE17 is sufficient to initiate tumor formation, additional events may be
required to produce the full spectrum of characteristics of these complex lesions.
Alternatively, the MC3T3 system might not precisely mimic the cellular context of the
TRE17-translocated cells in ABC. Nevertheless, our results refute the prevailing model for
the pathogenesis of ABC, which posits that it originates from a local circulatory disturbance,
with resultant tissue damage. Our data instead suggest a direct role for TRE17 in
establishing a degradative and vascularized microenvironment.
This work further identifies MMPs as novel effectors of TRE17. Previous
immunohistochemistry showed that MMP-9 is expressed in the fibrous stroma of ABC, but
the cells responsible for its production had not been determined (Kumta et al., 2003).
Furthermore, it was unclear whether MMP-9 had a causal role in ABC pathogenesis, or was
produced secondarily as a result of tissue damage and inflammation. Our finding that
TRE17 directly induces its production supports the former scenario, and suggests that
MMP-9 is a relevant effector of TRE17 in vivo.
There are multiple means by which MMP-9 and MMP-10 could contribute to ABC
pathogenesis. Both of these MMPs have previously been implicated in remodeling/
degradation of bone matrix, under physiological and pathological conditions (Bord et al.,
1998; Giambernardi et al., 1998; Engsig et al., 2000; Sternlicht and Werb, 2001; Onodera et
al., 2002; Tolboom et al., 2002; Kumta et al., 2003; Haeusler et al., 2005; Barksby et al.,
2006; Kanangat et al., 2006). MMP-9 and MMP-10 have multiple substrates including other
MMPs, which induces their zymogenic activation (Sternlicht and Werb, 2001; Van den
Steen et al., 2002; Krampert et al., 2004), potentially further contributing to the degradative
microenvironment in ABC. They can also proteolyze components of the ECM, which serves
not only to degrade the ECM but also to liberate matrix-bound growth factors that further
promote inflammation and angiogenesis (Sternlicht and Werb, 2001). For example,
numerous studies indicate that MMP-9 plays an important role in release of VEGF from
bone and cartilage matrix to promote angiogenesis and vascular permeability (Vu et al.,
1998; John and Tuszynski, 2001; Rundhaug, 2005; Ghajar et al., 2008). MMP-9 has also
been proposed to contribute to angiogenesis by degrading the endothelial and interstitial
matrix to facilitate endothelial cell migration and branching. Thus, the known functions of
MMP-9 are fully consistent with the histological features of ABC, which contain numerous
capillaries and extravasated blood. Future studies aimed at blocking MMP-9 expression/
activity will determine whether it is indeed required for the extensive vascularization
observed in our xenograft model.
Our studies further dissect the mechanism by which TRE17 induces MMP expression.
Induction of MMP-9 and MMP-10 is dependent on TRE17’s USP activity, but not its ability
to bind Arf6. Furthermore, NFκB is required for transcriptional induction of MMP-9.
Activation of NFκB is also dependent on TRE17’s USP activity, and is partially mediated
through RhoA/ROCK. The substrate(s) of TRE17’s USP domain and the mechanism by
which it leads to activation of RhoA remain to be determined. Previous work showed that
RhoA can be ubiquitinated to trigger its proteasomal degradation (Wang et al., 2003; Bryan
et al., 2005; Wang et al., 2006). However, it is unlikely that TRE17 functions by de-
ubiquitinating and stabilizing RhoA, since total RhoA levels are unaffected by TRE17. A
more likely possibility is that TRE17’s USP domain targets a guanine nucleotide exchange
factor (GEF) for RhoA to rescue it from proteasomal degradation.
Since inhibition of RhoA/ROCK only partially attenuated activation of NFκB by TRE17,
this suggests that TRE17 functions through additional parallel pathways, in a manner that
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requires its USP activity. One possibility is that it might de-ubiquitinate a component of the
NFκB regulatory pathway. NFκB activation is exquisitely controlled by a complex array of
ubiquitination and phosphorylation events (Hacker and Karin, 2006; Sebban et al., 2006).
Notably, three other USPs, CYLD, A20, and USP11, have previously been linked to NFκB
regulation (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003;
Wertz et al., 2004; Yamaguchi et al., 2007). However, in contrast to TRE17, they function
as negative regulators of NFκB, suggesting that TRE17 targets a distinct substrate from
these other USPs.
In conclusion, this work defines a signaling pathway, from TRE17->RhoA/ROCK->NFκB-
>MMP-9, which we propose contributes to ABC pathogenesis. Our results demonstrate that
TRE17’s USP activity and NFκB are required for MMP-9 induction, raising the possibility
that development of USP-specific inhibitors or NFκB antagonists might be effective novel
strategies for the treatment of these tumors.
MATERIALS AND METHODS
Cell culture
HeLa were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal
bovine serum (FBS), penicillin and streptomycin (P/S), sodium pyruvate and GlutaMax
(Invitrogen). The murine pre-osteoblast cell line MC-3T3-E1 (Clone 14) (referred to
hereafter as MC3T3) was obtained from ATCC, and grown in α-Modified Eagle Media (α-
MEM) with tetracyclin-free FBS, P/S, sodium pyruvate, GlutaMax, and G418 (400 μg/ml).
Both lines were maintained at 37°C in 5% CO2. Human fetal osteoblast hFOB1.19 cells
were grown in 1:1 DMEM without phenol red: Ham’s F12, with the same supplements and
G418 (300 μg/ml active), and kept at 34 °C in 5% CO2.
Antibodies and reagents
Antibodies for HA, actin, p65, and RhoA were from Santa Cruz Biotechnology, Inc. Anti-
human MMP-9 (AF911), anti-mouse MMP-9 (MAB9091), and anti-human MMP-10
(MAB9101) were from R&D systems. Gelatin agarose was from Sigma. TRE17 was
detected using anti-HA, or an antibody generated against the N-terminus of TRE17.
Y27632, Bay11-7082, wedelolactone, SC514, and IKK Inhibitor XI (PS1145) were from
EMD Biosciences.
Generation of MC3T3 cell lines
TRE17 cDNAs (TRE17(long), TRE17(short), TRE17(long)/USP-, and TRE17(A6-) were
subcloned into pBI-L (Clontech), which contains a bi-directional tet/dox-inducible promoter
that drives simultaneous expression of TRE17 and firefly luciferase. Resulting plasmids
were AseI-digested, then ligated to AseI-digested pN1βactin-rtTA2S-IRES-EGFP (Welman
et al., 2006). As negative control, pBI-L encoding luciferase alone was ligated to pN1βactin-
rtTA2S-M2-IRES-GFP to generate pSMV (super module vector) (Welman et al., 2006).
MC3T3 cells were transfected with the pSMV-derived constructs, then selected in medium
containing tet-free FBS and G418 (400 μg/ml). GFP-positive cells were isolated from the
G418-resistant pool by flow cytometry.
Detection of MMPs from Conditioned Medium
Cells were starved under serum-free conditions for 24-48 hours prior to harvesting.
Conditioned medium (CM) was subjected to low speed centrifugation to remove cell debris.
To monitor MMP-9, CM was supplemented with protease inhibitors, incubated with gelatin
agarose beads (Sigma) at 4°C for 6 hr, washed three times in PBS, then subjected to
immunoblotting. For zymography assays, gelatin agarose purified MMP-9 was fractionated
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on 8% gels containing 30 mg/ml gelatin (Sigma). Gels were washed with 2.5% Triton
X-100, incubated in substrate buffer (50mM Tris-HCl pH 8.0, 5mM CaCl2) at 37°C for 36
hr, then stained with Coommassie Brilliant Blue. To detect MMP-10, CM was precipitated
with 10% trichloroacetic acid. Pellets were washed twice in cold acetone, air dried, then
fractionated by SDS-PAGE.
Reverse transcription-quantitative PCR
RNA was extracted with Trizol (Invitrogen). Reverse transcription reactions were performed
on 1-2 μg of total RNA using a Superscript First-Strand Synthesis System kit (Invitrogen).
Real time PCR was performed using TaqMan probes on an ABI Prism 7900 system.
Relative expression levels were determined from a standard curve of serial dilutions of
cDNA samples and normalized to GAPDH levels. Primer sequences are available upon
request.
Luciferase Assays and EMSA
NFκB-dependent pBIIx (Zhong et al., 1997) and human MMP-9 promoter (Liu et al., 2006)
reporter constructs have been previously described. β-actin promoter-driven Renilla
luciferase reporter was used for normalization. HA-tagged TRE17 constructs were described
previously (Masuda-Robens et al., 2003; Martinu et al., 2004; Shen et al., 2005). Cells were
seeded in 35 mm wells, transfected with Lipofectamine 2000 or FuGENE6, starved, then
treated with drugs as indicated. Dual luciferase assays were performed according to
manufacturer instructions (Promega). Evaluations of statistical significance were conducted
with student’s t test. A two-tail p value < 0.05 was considered statistically significant.
EMSA was performed as previously described (Solt et al., 2007).
Immunofluorescence microscopy
Cells were seeded on coverslips, transfected using FuGENE6, then treated as described
previously (Masuda-Robens et al., 2003). Samples were viewed on a Zeiss confocal
microscope with LSM510 software, using excitation wavelengths of 488 nm (FITC), 546
nm (Cy3), or 358 nm (DAPI).
RhoA activity and TRE17-Arf6 binding assays
For RhoA activity assays, cells were lysed in RBD buffer (20 mM HEPES pH 7.5, 1%
Nonidet P-40, 10% glycerol, 1 mM EDTA, 150 mM NaCl, 10 mM MgCl2, 1 mM Na3VO4,
1 mM phenylmethylsulfonyl fluoride, pepstatin, leupeptin and aprotinin). Extracts were
precipitated with 20 μg of glutathione-S-transferase (GST) fused to the Rho binding domain
of Rhotekin conjugated to agarose for 2 hr, washed three times in RBD buffer, then
immunoblotted with RhoA antibody. Association of TRE17 and Arf6 was monitored as
described (Martinu et al., 2004).
Xenografting, Bioluminescence Imaging, and histology
All mouse procedures were in accordance with University of Pennsylvania IACUC. Nude
mice (Jackson Laboratories) were fed water with dox (1 mg/ml containing 5% sucrose) for
1-2 weeks before xenografting. MC3T3 cell lines were pre-treated with dox one day before
subcutaneous injection (2.5E6 cells per site). For dox-treated animals, 9 mice were injected
per cell line; dox was maintained in water for duration of the experiment. For animals not
treated with dox, 3 mice were injected per cell line.
For bioluminescence imaging, mice were anaesthetized with Avertin. Animals were injected
intraperitoneally with D-luciferin (Biotium; 120 μl at 25 mg/ml), and imaged within 8-20
minutes using the Xenogen In Vivo Imaging System. Tumors were paraffin-embedded and
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histological analysis was performed by the Abramson Cancer Center Pathology Core of the
University of Pennsylvania. Sections were subjected to immunohistochemistry using
antibodies against TRE17 or MMP-9 (R&D, AF909).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TRE17 induces secretion of MMP-9 and MMP-10 in a USP-dependent manner
(A) hFOB1.19 human fetal osteoblasts were transfected with the indicated HA-tagged
TRE17 constructs, then serum-starved. MMP-9 and MMP-10 in the CM were concentrated
as described in Experimental Procedures, and detected by immunoblotting. Whole cell
lysates were blotted for TRE17 (arrowheads indicate migration of TRE17(long) and
TRE17(short) isoforms; asterisk denotes non-specific (ns) band recognized by antibody),
and actin as a loading control. (B) Domain structure of TRE17 alleles. TBC, TBC domain; C
and H, cysteine and histidine subdomains of the USP domain. TRE17(long)/USP- and
TRE17/A6- harbor point mutations in the indicated domains, as detailed in Experimental
Procedures. (C) MC3T3 osteoblasts stably expressing HA-tagged TRE17(long) or
TRE17(A6-) in a doxycycline (dox)-inducible manner were treated with dox (2 μg/ml) for
24 hrs. Cell extracts were immunoprecipitated with anti-HA, then blotted with anti-Arf6 (top
panel) or anti-TRE17 (bottom panel). I.P., anti-HA immunoprecipitate; WCL, whole cell
lysate. (D) Stable MC3T3 cell lines expressing the indicated TRE17 alleles were grown with
or without dox for 24 hrs, then starved for 24 hrs in the continued absence or presence of
dox. MMP-9 was purified from the CM then subjected to blotting, or zymography to detect
gelatinolytic activity. (E) HeLa cells were transfected as indicated, and accumulation of
MMP-9 and MMP-10 in the CM was monitored as in (A).
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Figure 2. TRE17 induces MMP expression on a transcriptional level
(A) hFOB1.19 or (B) HeLa cells were transfected, then serum-starved for 24-48 hours.
MC3T3-derived cell lines (C) were treated with or without dox for 24 hrs, then starved for
an additional 24 hrs. For all three cell systems RNA was isolated, and RT-qPCR was
performed to monitor MMP-9 and MMP-10 mRNA, using two independent primer pairs for
each (denoted MMP9-1 and -2, and MMP10-1 and -2), normalizing against GAPDH. For
hFOB1.19 and HeLa cells, data represent the mean ± SD of three experiments. Samples with
statistically significant differences from vector control cells are indicated (*, p<0.05; **,
p<0.01). D) hFOB1.19 or HeLa cells were co-transfected with the indicated TRE17
constructs and a luciferase reporter driven a fragment of the human MMP-9 promoter
encoding base pairs −674 to +3 relative to the transcription start site. Luciferase assays were
performed; data represent the mean ± SD of 4 experiments. Samples with statistically
significant differences from vector control cells are indicated (*, p<0.05; **, p<0.01).
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Figure 3. NFκB is required for induction of MMP-9 by TRE17
A) hFOB1.19 or HeLa cells were transfected with the indicated TRE17 constructs and either
a luciferase reporter driven by the WT MMP-9 promoter, or a mutant in which the NFκB
response element was ablated. Luciferase assays were performed; data represent the mean ±
SD of 4 experiments (*, p<0.05; **, p<0.01). (B) Left, hFOB1.19 were transfected as
indicated, then starved for 24 hrs. Middle, control or TRE17(long)/MC3T3 cells were
treated with dox, then starved in the presence of dox. Bay11-7082 was added at the indicated
micromolar concentration during starvation. Right, control or TRE17(long)/MC3T3 cells
were treated with Bay11-7082 (B, 10 μM) or U0126 (U, 50 μM) where indicated. For all
three, MMP-9 in the CM was detected; whole cell lysates were blotted with TRE17 and
actin antibodies. (C) MMP-9 was assayed as in (B), except the IKK inhibitors wedelolactone
(W, 50 μM), SC514 (SC, 100 μM) or IKK Inhibitor XI (XI, 20 μM) were used where
indicated.
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Figure 4. TRE17(long) activates NFκB in a USP-dependent manner
(A) hFOB1.19 or Hela cells were co-transfected with the indicated TRE17 construct and a
luciferase reporter driven by tandem NFκB response elements. Cells were starved and
luciferase assays were performed. Data represent the mean ± SD of four independent
experiments (*, p<0.05; **, p<0.01). (B) EMSAs were performed in transiently transfected
HeLa (top), or MC3T3 lines expressing vector, TRE17(long), or TRE17(long)/USP-
(bottom). As a positive control, vector control cells were treated with TNFα (10 ng/ml, 30
minutes) where indicated. (C) hFOB1.19 cells were transfected with the indicated TRE17
construct, starved for 24 hr, then stained with anti-HA, anti-p65, and DAPI. Arrows
highlight transfected cells. Scale bar, 20 μm.
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Figure 5. RhoA and ROCK partially mediate activation of NFκB by TRE17
(A) RhoA activity was measured in transiently transfected hFOB1.19 (left), HeLa (middle),
and MC3T3 cell lines (right). Cell extracts were subjected to pulldowns using a GST fusion
of the RhoA·GTP-binding domain (RBD) of Rhotekin, followed by blotting with anti-RhoA.
Active RhoA, RBD pulldowns; total RhoA, whole cell lysates. (B) hFOB1.19 or HeLa were
transfected with NFκB-luciferase and TRE17(long), in the absence or presence of dominant
negative RhoA (RhoAN19) or Y27632, and subjected to luciferase assays. (C) Control or
TRE17(long)/MC3T3 cells were treated with dox for 24 hrs, then starved with dox and the
indicated concentration of Y27632 (μM) for 24 hrs. MMP-9 in the CM was detected by
immunoblotting and zymography. Whole cell extracts were blotted to confirm TRE17 and
actin levels.
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Figure 6. TRE17(long) induces formation of tumors that recapitulate multiple features of ABC
in a USP-dependent manner
(A) In vivo bioluminescence imaging of mice injected with MC3T3 cell lines expressing
TRE17(long), TRE17(long)/USP-, or luciferase alone. (B) Left, macroscopic images of
tumor and injection site of mice injected with vector or TRE17(long)-expressing MC3T3.
Right, H&E stain of TRE17(long) tumor section. Arrowheads highlight vascular elements.
(C) Immunohistochemistry was performed on serial sections of TRE17(long)-induced tumor
using antibodies against TRE17 and MMP-9. Nuclear staining for TRE17 is non-specific;
only central cells exhibit specific cytoplasmic staining of TRE17.
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